Cognition Therapeutics Inc. Common Stock (CGTX)
Stock · NASDAQ · Health Care
$0.7311as of 10/16/2026
Price chart
Active signals
CGTX Signal Track Record
How signals performed across all stocks →What CGTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +1.9% | 51% | October 1, 2026 |
| Bollinger Band BreakdownActive now | 20 | -1.3% | 45% | September 23, 2026 |
| Bollinger Band Breakout | 16 | -6.5% | 31% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -14.1% | 40% | July 23, 2024 |
| Any 20-session window (baseline) | -5.9% | 37% |
Computed by MarketWall from daily closing prices since July 26, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, whic…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 14
- Website
- cogrx.com/
Fundamentals
- 1-day range
- $0.7134$0.7874
- Market cap
- $101.13M
- P/E (trailing)
- —
- P/E (forward)
- -3.32
- EPS (trailing)
- $-0.20
- Dividend yield
- —
- Beta
- 1.80
- Avg. volume
- 505.6K
Forecasts
3 analyst ratings
Cognition Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CGTXCognition Therapeutics Inc. Common Stock$0.73▼ 0.41%Market cap $101.13MP/E —$0.5501$2
- PTHSPelthos Therapeutics Inc. Common Stock$20.15▼ 0.54%Market cap $102.36MP/E —$18.19$37.5
- KLRSKalaris Therapeutics Inc. Common Stock$2▼ 8.68%Market cap $99.69MP/E —$2.35$11.88
- BDTXBlack Diamond Therapeutics Inc. Common Stock$1.72▼ 1.15%Market cap $110.02MP/E —$1.6$4.94
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $0.73 | ▼ 0.41% | $0.5501$2 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $20.15 | ▼ 0.54% | $18.19$37.5 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $2 | ▼ 8.68% | $2.35$11.88 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $1.72 | ▼ 1.15% | $1.6$4.94 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesinebenzinga · 10/13/2026
- Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLBYahoo · 9/29/2026
- Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of ZervimesineBenzinga · 9/29/2026
Insider Activity
Insider Actions →- Ellen B. Richstone · June 17, 2026 · Grant25.0K
- BIOS Fund II QP, LP · June 17, 2026 · Grant25.0K
- Jack A. Khattar · June 17, 2026 · Grant25.0K
- Brett P. Monia · June 17, 2026 · Grant25.0K
- Peggy Wallace · June 17, 2026 · Grant25.0K
- John Brendan Doyle · May 1, 2026 · Tax Withholding8.6K @ $1.28
- John Brendan Doyle · April 16, 2026 · Buy10.0K @ $1.13
- Anthony Caggiano · April 16, 2026 · Buy10.0K @ $1.11
- Lisa Ricciardi · April 16, 2026 · Buy9.2K @ $1.1
Institutional Ownership
March 31, 2026
- Total shares held
- 20.93M
- Total value held
- $15.74M
- Institutional holders
- 73
- Unknown6.00M
- Unknown3.00M
- Unknown2.89M
- Unknown1.12M
- Unknown997.0K
- Unknown968.4K
- Unknown920.2K
- Unknown549.0K
- Unknown431.0K
- Unknown400.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.